SCHEMBL347104

SCHEMBL347104

CCCN1CCC2(CC1)CNC2

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.47
KDM4E B2RXH2 1/20 0.41
DRD2 P14416 6/20 0.33
SIGMAR1 Q99720 1/20 0.33
DRD3 P35462 3/20 0.33
CYP2D6 P10635 2/20 0.32
CYP3A4 P08684 1/20 0.32
S1PR1 P21453 1/20 0.32
S1PR3 Q99500 1/20 0.32
S1PR5 Q9H228 1/20 0.32
DRD4 P21917 1/20 0.31
KMT2A Q03164 1/20 0.31
EPHX1 P07099 1/20 0.30
EPHX2 P34913 1/20 0.30
CYP1A2 P05177 1/20 0.30
HRH3 Q9Y5N1 1/20 0.30
ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9851585 0.88 TSHR (0.53) TSHRKDM4EDRD2DRD3CYP2D6
SCHEMBL23921701 0.88 TSHR (0.44) TSHRDRD2SIGMAR1DRD3S1PR1
SCHEMBL24970676 0.86 S1PR1 (0.46) TSHRDRD2SIGMAR1DRD3S1PR1
SCHEMBL23135107 0.86 TSHR (0.61) TSHRKDM4EDRD3CYP2D6CYP3A4
SCHEMBL20153230 0.84 S1PR1 (0.49) TSHRSIGMAR1S1PR1S1PR3S1PR5
SCHEMBL21107507 0.84 KDM4E (0.43) TSHRKDM4EDRD2SIGMAR1DRD3
SCHEMBL12605245 0.82 TSHR (0.60) TSHRKDM4ECYP2D6CYP3A4KMT2A
SCHEMBL10263353 0.81 TSHR (0.50) TSHRKDM4EDRD3CYP2D6CYP3A4
SCHEMBL29320463 0.79 TSHR (0.41) TSHRSIGMAR1CYP2D6CYP3A4CYP1A2
SCHEMBL25823724 0.78 ALOX15 (0.50) TSHRSIGMAR1CYP2D6CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017161028-A1 SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE KURA ONCOLOGY, INC. (US) 2017-09-21 WO disclosed
EP-2520568-B1 Spirocyclic nitriles as inhibitors of protease SANOFI SA (FR) 2015-09-09 EP disclosed
US-20140073662-A1 Spirocyclic nitriles as protease inhibitors SANOFI (FR) 2014-03-13 US disclosed
US-8609681-B2 Spirocyclic nitriles as protease inhibitors SANOFI (FR) 2013-12-17 US disclosed
EP-2520568-A1 Spirocyclic nitriles as inhibitors of protease SANOFI (FR) 2012-11-07 EP disclosed
EP-2032535-B1 SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS SANOFI SA (FR) 2012-08-01 EP disclosed
US-20120015933-A1 Spirocyclic nitriles as protease inhibitors SANOFI-AVENTIS (FR) 2012-01-19 US disclosed
US-8039480-B2 Spirocyclic nitriles as protease inhibitors SANOFI-AVENTIS (FR) 2011-10-18 US disclosed
US-20090275523-A1 Spirocyclic nitriles as protease inhibitors SANOFI-AVENTIS (FR) 2009-11-05 US disclosed
EP-2032535-A1 SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS Sanofi-Aventis (FR) 2009-03-11 EP disclosed
WO-2007137738-A1 SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS SANOFI-AVENTIS (DE) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275523-A1 Spirocyclic nitriles as protease inhibitors CTRL, SERPINB1, PREP TSHR 4046/4885KDM4E 4259/4885DRD2 4586/4885
US-20120015933-A1 Spirocyclic nitriles as protease inhibitors CTRL, SERPINB1, PREP TSHR 4046/4885KDM4E 4259/4885DRD2 4586/4885
US-20140073662-A1 Spirocyclic nitriles as protease inhibitors CTRL, SERPINB1, PREP TSHR 4046/4885KDM4E 4259/4885DRD2 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.